LOS ANGELES, CA–(Marketwired – May 9, 2016) – Marathon Patent Group, Inc. (NASDAQ: MARA) (“Marathon”), a patent licensing and commercialization company, announced that its wholly owned subsidiary Orthophoenix LLC, entered into a license agreement with Titanium2Bone, Inc. The consideration to be paid by Titanium2Bone to Orthophoenix and all other commercial terms of the license agreement are confidential.
Titanium2Bone, while not the subject of an enforcement action by Orthophoenix, has taken a license to certain Orthophoenix patents. The license agreement establishes a reasonable royalty rate related to its patent portfolio.
Rick Sanchez, Executive VP of Licensing for Marathon stated, “We are pleased to have entered into a licensing agreement with Titanium2Bone, thereby establishing a recurring royalty rate on licensed products. Agreements like these are a natural win-win for both Orthophoenix and Titanium2bone. Furthermore, this agreement is illustrative of the fundamental strength and value of the Orthophoenix portfolio of assets.”
Volker Ludwig, President of Titanium2Bone, continued, “By being proactive and choosing to take a license to certain Orthophoenix patents, we are acting in the best interest of both our company and customers. It is not uncommon that patent infringement related matters can extend beyond not only a manufacturer, but also to those using the patented invention itself in practice, a Doctor for instance. Our taking a license to the Orthophoenix patents assures that we, and them, are free to make, use, and sell Titanium2Bone products, without fear of an infringement action being brought.”
About Marathon Patent Group
Marathon is a patent acquisition and monetization company. The Company acquires patents from a wide-range of patent holders from individual inventors to Fortune 500 companies. Marathon’s strategy of acquiring patents that cover a wide-range of subject matter allows the Company to achieve diversity within its patent asset portfolio. Marathon generates revenue with its diversified portfolio through actively managed concurrent patent rights enforcement campaigns. This approach is expected to result in a long-term, diversified revenue stream. To learn more about Marathon Patent Group, visit www.marathonpg.com.
Titanium2Bone is an American company founded in 2015 with the primary focus on the high quality KMC Kyphoplasty System used for more than 20,000 cases in Europe and the innovative Mendec Spine HV System. A system with an outstanding high viscosity pre-dosed spine cement in a closed mixing device.
Safe Harbor Statement
Certain statements in this press release constitute “forward-looking statements” within the meaning of the federal securities laws. Words such as “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “predict,” “forecast,” “project,” “plan,” “intend” or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company’s filings with the Securities and Exchange Commission (the “SEC”), not limited to Risk Factors relating to its patent business contained therein. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.